Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomised Double-blind Study of Anifrolumab in Proliferative Lupus Nephritis
2015-001442-29Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) comparing Anifrolumab + Standard of Care with Placebo + Standard of Care (2 arms). Primary endpoint: Change in 24-hour urine protein to creatinine ratio at Week 52. Started Oct 2015; status: completed.
02
Drugs
anifrolumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2015-001442-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001442-29.